KR20090082467A - Ｃ형 간염 바이러스 억제제 - Google Patents
Ｃ형 간염 바이러스 억제제 Download PDFInfo
- Publication number
- KR20090082467A KR20090082467A KR1020097011785A KR20097011785A KR20090082467A KR 20090082467 A KR20090082467 A KR 20090082467A KR 1020097011785 A KR1020097011785 A KR 1020097011785A KR 20097011785 A KR20097011785 A KR 20097011785A KR 20090082467 A KR20090082467 A KR 20090082467A
- Authority
- KR
- South Korea
- Prior art keywords
- methoxy
- carbamoyl
- oxy
- prolineamide
- isoquinolinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CNC1(C*(*)C1)C(NS(*)(=O)=O)=O Chemical compound CNC1(C*(*)C1)C(NS(*)(=O)=O)=O 0.000 description 8
- WMSPXQIQBQAWLL-UHFFFAOYSA-N NS(C1CC1)(=O)=O Chemical compound NS(C1CC1)(=O)=O WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 description 6
- RTKFCGMFEQPEMU-UHFFFAOYSA-N NS(C1(CC1)C1=CCCCC1)(=O)=O Chemical compound NS(C1(CC1)C1=CCCCC1)(=O)=O RTKFCGMFEQPEMU-UHFFFAOYSA-N 0.000 description 2
- JQLQQPTXRBSHPF-UHFFFAOYSA-N C=CCC1(CC1)S(N)(=O)=O Chemical compound C=CCC1(CC1)S(N)(=O)=O JQLQQPTXRBSHPF-UHFFFAOYSA-N 0.000 description 1
- KPGCMYRJDKUDCT-SVRRBLITSA-N C=C[C@H](C1)[C@H]1C(NS(C1CC1)(=O)=O)=O Chemical compound C=C[C@H](C1)[C@H]1C(NS(C1CC1)(=O)=O)=O KPGCMYRJDKUDCT-SVRRBLITSA-N 0.000 description 1
- VGHBWKACJXNKAF-HZGVNTEJSA-N C=C[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)N Chemical compound C=C[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)N VGHBWKACJXNKAF-HZGVNTEJSA-N 0.000 description 1
- SKKGMOAQEAQNGO-ZGBMLECWSA-N CC(C)(C)C(C(N(C[C@@H](C1)Oc(nc2)c(cc(cc3)Cl)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc(cc1)cc(F)c1F Chemical compound CC(C)(C)C(C(N(C[C@@H](C1)Oc(nc2)c(cc(cc3)Cl)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc(cc1)cc(F)c1F SKKGMOAQEAQNGO-ZGBMLECWSA-N 0.000 description 1
- KLOCPFINBSKKKA-MTYSSGSHSA-N CC(C)(C)C(C(N(C[C@@H](C1)Oc(nc2)c(cc(cc3)Cl)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc(cn1)ccc1OC(F)F Chemical compound CC(C)(C)C(C(N(C[C@@H](C1)Oc(nc2)c(cc(cc3)Cl)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc(cn1)ccc1OC(F)F KLOCPFINBSKKKA-MTYSSGSHSA-N 0.000 description 1
- LALJURJCIKBJGH-DQOAMNSGSA-N CC(C)(C)C(C(N(C[C@@H](C1)Oc(nc2)c(cc(cc3)Cl)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1cc(S(N(C)C)(=O)=O)ccc1 Chemical compound CC(C)(C)C(C(N(C[C@@H](C1)Oc(nc2)c(cc(cc3)Cl)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1cc(S(N(C)C)(=O)=O)ccc1 LALJURJCIKBJGH-DQOAMNSGSA-N 0.000 description 1
- XDPXYKMLGIKDGV-UHFFFAOYSA-N CC(C)(C)C(C(O)=O)Nc1ccccc1 Chemical compound CC(C)(C)C(C(O)=O)Nc1ccccc1 XDPXYKMLGIKDGV-UHFFFAOYSA-N 0.000 description 1
- KMYLDHSHCQGQHW-LDHQFIGFSA-N CC(C)(C)C[C@@H](C(N(C[C@@H](C1)Oc(c2c3ccc(Cl)c2)ncc3OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1cc(C(N(C)C)=O)ccc1 Chemical compound CC(C)(C)C[C@@H](C(N(C[C@@H](C1)Oc(c2c3ccc(Cl)c2)ncc3OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1cc(C(N(C)C)=O)ccc1 KMYLDHSHCQGQHW-LDHQFIGFSA-N 0.000 description 1
- SPGDRXRIVPMUCK-UHFFFAOYSA-N CC(C)(C)NS(CCCCl)(=O)=O Chemical compound CC(C)(C)NS(CCCCl)(=O)=O SPGDRXRIVPMUCK-UHFFFAOYSA-N 0.000 description 1
- QHHXJNLBANEKFF-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C1)Oc2c(cc(cc3)Cl)c3ccn2)C1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC(C1)Oc2c(cc(cc3)Cl)c3ccn2)C1C(O)=O)=O QHHXJNLBANEKFF-UHFFFAOYSA-N 0.000 description 1
- PKFSEWUBSHYLOB-WUJWULDRSA-N CC(C)(C)OC(N(CC(C1)Oc2c(cc(cc3)F)c3ccn2)[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC(C1)Oc2c(cc(cc3)F)c3ccn2)[C@@H]1C(O)=O)=O PKFSEWUBSHYLOB-WUJWULDRSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N CC(C)(C)OC(N(CCC1)[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1C(O)=O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
- BENKAPCDIOILGV-RQJHMYQMSA-N CC(C)(C)OC(N(C[C@@H](C1)O)[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](C1)O)[C@@H]1C(O)=O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 1
- YFRAGGNFPQCAPN-NPCAHTBFSA-N CC(C)(C)OC(N(C[C@@H](C1)Oc2c(C=CC(C3)OC)c3cc(OC)n2)C1C(O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](C1)Oc2c(C=CC(C3)OC)c3cc(OC)n2)C1C(O)=O)=O YFRAGGNFPQCAPN-NPCAHTBFSA-N 0.000 description 1
- RFDWVLAOYZWXGJ-QAPCUYQASA-N CC(C)(C)OC(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3c3OCCN(C)c3n2)[C@@H]1C([NH]=C)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3c3OCCN(C)c3n2)[C@@H]1C([NH]=C)=O)=O RFDWVLAOYZWXGJ-QAPCUYQASA-N 0.000 description 1
- DGMYUOIUPUZCDM-AEFFLSMTSA-N CC(C)(C)OC(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3cc(OC)n2)[C@@H]1C(C)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3cc(OC)n2)[C@@H]1C(C)=O)=O DGMYUOIUPUZCDM-AEFFLSMTSA-N 0.000 description 1
- NBXGDPBFRRQZEV-UHFFFAOYSA-N CC(C)(C)OC(NS(C1CC1)(=O)=O)=O Chemical compound CC(C)(C)OC(NS(C1CC1)(=O)=O)=O NBXGDPBFRRQZEV-UHFFFAOYSA-N 0.000 description 1
- CHQWLSPZWMQDMQ-SAUVGFCRSA-N CC(C)C(C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3cc(OC)n2)[C@@H]1C(C)=O)=O)Nc1ccccc1 Chemical compound CC(C)C(C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3cc(OC)n2)[C@@H]1C(C)=O)=O)Nc1ccccc1 CHQWLSPZWMQDMQ-SAUVGFCRSA-N 0.000 description 1
- JVLCLUQRUWCMGU-DBSPZYFTSA-N CC(C)C(C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3ccn2)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1nc(OC)cc(OC)n1 Chemical compound CC(C)C(C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3ccn2)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1nc(OC)cc(OC)n1 JVLCLUQRUWCMGU-DBSPZYFTSA-N 0.000 description 1
- DXQZISQNYYQIEU-BHKAWDCFSA-N CC(C)C(C(N(C[C@@H](C1)Oc2nccc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1ccc(C(F)(F)F)cn1 Chemical compound CC(C)C(C(N(C[C@@H](C1)Oc2nccc3c2ccc(OC)c3)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1ccc(C(F)(F)F)cn1 DXQZISQNYYQIEU-BHKAWDCFSA-N 0.000 description 1
- YBOXXHKPMJKJLB-XYHZYDHVSA-N CC(C)[C@H](C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3ccn2)[C@@H]1C(NC([C@@]1(C2)C=C)C12C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1nc(OC)nc(OC)n1 Chemical compound CC(C)[C@H](C(N(C[C@@H](C1)Oc2c(ccc(OC)c3)c3ccn2)[C@@H]1C(NC([C@@]1(C2)C=C)C12C(NS(C1CC1)(=O)=O)=O)=O)=O)Nc1nc(OC)nc(OC)n1 YBOXXHKPMJKJLB-XYHZYDHVSA-N 0.000 description 1
- CMQRMZLDLVWERJ-HIFRSBDPSA-N CC([C@H](C1)NC[C@@H]1Oc1c(ccc(OC)c2)c2cc(OC)n1)=O Chemical compound CC([C@H](C1)NC[C@@H]1Oc1c(ccc(OC)c2)c2cc(OC)n1)=O CMQRMZLDLVWERJ-HIFRSBDPSA-N 0.000 description 1
- KHEZKDIWDCVMTL-UHFFFAOYSA-N CCCNC(C1(CC1)S(N)(=O)=O)=O Chemical compound CCCNC(C1(CC1)S(N)(=O)=O)=O KHEZKDIWDCVMTL-UHFFFAOYSA-N 0.000 description 1
- PRBJPWWWRIEGTA-JFAAMYIWSA-N CCOc1n[s]nc1NC(C(C)(C)C)C(N(C[C@@H](C1)Oc(nc2)c(cc(cc3)Cl)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O Chemical compound CCOc1n[s]nc1NC(C(C)(C)C)C(N(C[C@@H](C1)Oc(nc2)c(cc(cc3)Cl)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O PRBJPWWWRIEGTA-JFAAMYIWSA-N 0.000 description 1
- VFYMVJNGXBABEF-UHFFFAOYSA-N COC(C(CC1)=C2C=C1N)=CCCC=C2[O]#C Chemical compound COC(C(CC1)=C2C=C1N)=CCCC=C2[O]#C VFYMVJNGXBABEF-UHFFFAOYSA-N 0.000 description 1
- PKGOAHVKZIEDOX-UHFFFAOYSA-N COc(cc(ccnc1Cl)c1c1)c1F Chemical compound COc(cc(ccnc1Cl)c1c1)c1F PKGOAHVKZIEDOX-UHFFFAOYSA-N 0.000 description 1
- SWPLDRGOIDIKQH-UHFFFAOYSA-N COc(cc1)cc2c1c(Cl)nc(-c1ncc[s]1)c2 Chemical compound COc(cc1)cc2c1c(Cl)nc(-c1ncc[s]1)c2 SWPLDRGOIDIKQH-UHFFFAOYSA-N 0.000 description 1
- WWJAKIIHTOQSBE-CGUBGCFPSA-N COc(cn1)c(ccc(Cl)c2)c2c1O[C@H](C[C@H]1C(N[C@](C2)([C@@H]2C=C)C(NS(C2CC2)(=O)=O)=O)=O)CN1C(C(CCCCCC=C)Nc(cn1)ccc1OC)=O Chemical compound COc(cn1)c(ccc(Cl)c2)c2c1O[C@H](C[C@H]1C(N[C@](C2)([C@@H]2C=C)C(NS(C2CC2)(=O)=O)=O)=O)CN1C(C(CCCCCC=C)Nc(cn1)ccc1OC)=O WWJAKIIHTOQSBE-CGUBGCFPSA-N 0.000 description 1
- DVHOIKSDQCZHOV-UHFFFAOYSA-N COc1c(ccnc2Cl)c2ccc1 Chemical compound COc1c(ccnc2Cl)c2ccc1 DVHOIKSDQCZHOV-UHFFFAOYSA-N 0.000 description 1
- DIAMRSWZRAZRSF-UHFFFAOYSA-N COc1ccc2c(Cl)nc(OC)cc2c1 Chemical compound COc1ccc2c(Cl)nc(OC)cc2c1 DIAMRSWZRAZRSF-UHFFFAOYSA-N 0.000 description 1
- AAYHAFZXFMIUSN-UHFFFAOYSA-N NS(C1CCCCC1)(=O)=O Chemical compound NS(C1CCCCC1)(=O)=O AAYHAFZXFMIUSN-UHFFFAOYSA-N 0.000 description 1
- YWUCOQGBXQHOJM-UHFFFAOYSA-N O=C(c1c2)NC=Cc1ccc2Cl Chemical compound O=C(c1c2)NC=Cc1ccc2Cl YWUCOQGBXQHOJM-UHFFFAOYSA-N 0.000 description 1
- WKCRTQPANFLWRL-UHFFFAOYSA-N O=C1NC=Cc2c(CCO3)c3ccc12 Chemical compound O=C1NC=Cc2c(CCO3)c3ccc12 WKCRTQPANFLWRL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86503406P | 2006-11-09 | 2006-11-09 | |
| US60/865,034 | 2006-11-09 | ||
| US11/934,840 US7772180B2 (en) | 2006-11-09 | 2007-11-05 | Hepatitis C virus inhibitors |
| US11/934,840 | 2007-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090082467A true KR20090082467A (ko) | 2009-07-30 |
Family
ID=39304590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097011785A Withdrawn KR20090082467A (ko) | 2006-11-09 | 2007-11-08 | Ｃ형 간염 바이러스 억제제 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7772180B2 (https=) |
| EP (1) | EP2086963B1 (https=) |
| JP (1) | JP2010509359A (https=) |
| KR (1) | KR20090082467A (https=) |
| CN (1) | CN101541784B (https=) |
| AR (1) | AR063653A1 (https=) |
| AU (1) | AU2007319435A1 (https=) |
| BR (1) | BRPI0718625A2 (https=) |
| CA (1) | CA2669310A1 (https=) |
| CL (1) | CL2007003250A1 (https=) |
| EA (1) | EA200900676A1 (https=) |
| IL (1) | IL198248A0 (https=) |
| MX (1) | MX2009004888A (https=) |
| NO (1) | NO20091591L (https=) |
| NZ (1) | NZ576817A (https=) |
| PE (1) | PE20081344A1 (https=) |
| TW (1) | TW200826938A (https=) |
| WO (1) | WO2008060927A2 (https=) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| WO2007114926A2 (en) | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| SG174809A1 (en) * | 2007-05-03 | 2011-10-28 | Intermune Inc | Macrocyclic compounds useful as inhibitors of hepatitis c virus |
| JP2010526834A (ja) * | 2007-05-10 | 2010-08-05 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤 |
| WO2009005690A2 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| TWI487522B (zh) | 2007-12-21 | 2015-06-11 | 賽基艾維洛米斯研究股份有限公司 | Ｈｃｖ蛋白酶抑制劑及其用途（一） |
| RU2515318C2 (ru) | 2007-12-21 | 2014-05-10 | Авила Терапьютикс, Инк. | Ингибиторы протеазы вируса гепатита с и их применение |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| EP3613743B1 (en) | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| ES2437147T3 (es) * | 2008-02-04 | 2014-01-09 | Idenix Pharmaceuticals, Inc. | Inhibidores de serina proteasa macrocíclicos |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US8637542B2 (en) * | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| WO2009142842A2 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US20090285774A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| JP5788316B2 (ja) * | 2008-07-08 | 2015-09-30 | インテリカイン， エルエルシー | キナーゼインヒビターおよび使用方法 |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| KR20110075019A (ko) * | 2008-10-15 | 2011-07-05 | 인터뮨, 인크. | 치료용 항바이러스성 펩티드 |
| WO2010045542A2 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| KR101018330B1 (ko) | 2009-04-30 | 2011-03-04 | 한국외국어대학교 연구산학협력단 | 3,4-디히드로이소퀴놀리늄 유도체 및 이를 포함하는 약학 조성물 |
| EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
| US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| EP2461811B1 (en) | 2009-08-05 | 2016-04-20 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| CN102741270B (zh) * | 2009-09-28 | 2015-07-22 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
| US20110082182A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| US9193740B2 (en) * | 2009-10-19 | 2015-11-24 | Enanta Pharmaceuticals, Inc. | Bismacrocyclic compounds as hepatitis C virus inhibitors |
| CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CN102134240A (zh) * | 2010-06-29 | 2011-07-27 | 嘉兴宜博生物医药科技有限公司 | 一种6-氟-7-氮杂吲哚的合成方法 |
| EA201390532A1 (ru) * | 2010-10-08 | 2013-09-30 | Новартис Аг | Композиции сульфамидых ингибиторов ns3, содержащие витамин е |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제 |
| TWI674262B (zh) | 2011-01-10 | 2019-10-11 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| MX2014000648A (es) | 2011-07-19 | 2014-09-25 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y sus usos. |
| KR20140075693A (ko) | 2011-08-29 | 2014-06-19 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
| MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
| CA2865511A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| EP2882714B1 (en) * | 2012-08-08 | 2019-11-13 | Merck Patent GmbH | (aza-)isoquinolinone derivatives |
| MX2015003874A (es) | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US9611223B2 (en) | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP4585268A3 (en) | 2015-09-14 | 2025-10-15 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| CN109069658B (zh) | 2016-02-08 | 2022-10-14 | 西纳福克斯股份有限公司 | 用于靶向her2肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法 |
| WO2017137423A1 (en) * | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Improved sulfamide linkers for use in bioconjugates |
| CN109152844B (zh) | 2016-02-08 | 2022-11-22 | 西纳福克斯股份有限公司 | 用于治疗的含有磺酰胺接头的生物缀合物 |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| RU2754507C2 (ru) | 2016-06-24 | 2021-09-02 | Инфинити Фармасьютикалз, Инк. | Комбинированная терапия |
| CN113200933B (zh) * | 2021-05-19 | 2022-12-09 | 河南师范大学 | 不对称加成反应合成光学活性苯并羧酸酯类化合物的方法 |
| AU2023374710A1 (en) * | 2022-11-02 | 2025-06-19 | Philochem Ag | Carbonic anhydrase ix ligands for targeted delivery applications |
| WO2024149700A1 (en) * | 2023-01-12 | 2024-07-18 | Firmenich Sa | Process for preparation of sulfamoyl chloride |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0475255A3 (en) | 1990-09-12 | 1993-04-14 | F. Hoffmann-La Roche Ag | Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid |
| AP1019A (en) | 1996-10-18 | 2001-10-16 | Vertex Pharma | Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease. |
| ES2241157T3 (es) | 1997-08-11 | 2005-10-16 | Boehringer Ingelheim (Canada) Ltd. | Peptidos inhibidores de la hepatitis c. |
| EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| CN1498224A (zh) | 2000-07-21 | 2004-05-19 | ���鹫˾ | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
| ES2263687T3 (es) | 2000-11-20 | 2006-12-16 | Bristol-Myers Squibb Company | Inhibidores tripeptidicos de la hepatitis c. |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| DE60324552D1 (en) | 2002-05-20 | 2008-12-18 | Bristol Myers Squibb Co | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren |
| US20060199773A1 (en) | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
| ATE481106T1 (de) | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
| ES2361011T3 (es) | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| CA2515216A1 (en) | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
| WO2004101605A1 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
| MXPA05010338A (es) | 2003-04-02 | 2005-11-17 | Boehringer Ingelheim Int | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c. |
| ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
| CN1788006A (zh) | 2003-04-18 | 2006-06-14 | 安南塔制药公司 | 喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
| WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| RS20060197A (sr) | 2003-09-22 | 2008-09-29 | Boehringer Ingelheim International Gmbh., | Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa |
| WO2005037860A2 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| HRP20130098T1 (hr) | 2003-10-14 | 2013-02-28 | F. Hoffmann - La Roche Ag | MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2007532479A (ja) | 2003-11-20 | 2007-11-15 | シェーリング コーポレイション | Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター |
| EP1730167B1 (en) | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
| PL1713822T3 (pl) | 2004-01-30 | 2010-08-31 | Medivir Ab | Inhibitory proteazy serynowej HCV NS-3 |
| BRPI0509467A (pt) | 2004-03-30 | 2007-09-11 | Intermune Inc | compostos macrocìclicos como inibidores de replicação viral |
| WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
| EP1753775B1 (en) | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
| EP1763531A4 (en) | 2004-06-28 | 2009-07-01 | Boehringer Ingelheim Int | ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES |
| RS51974B (sr) | 2004-07-16 | 2012-02-29 | Gilead Sciences Inc. | Antivirusna jedinjenja |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| JP4914355B2 (ja) | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| CA2577812A1 (en) | 2004-08-27 | 2006-03-09 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease |
| US7375218B2 (en) | 2004-09-17 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic HCV protease inhibitors |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| MX2007004783A (es) | 2004-10-21 | 2007-05-11 | Pfizer | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2006220708B9 (en) | 2005-03-08 | 2013-01-17 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
| CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ563361A (en) | 2005-06-02 | 2011-02-25 | Schering Corp | HCV protease inhibitors in combination with food |
| US20060276404A1 (en) | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
| JP2008545748A (ja) | 2005-06-02 | 2008-12-18 | シェーリング コーポレイション | Ｃ型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物 |
| US20070004635A1 (en) | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
| NZ563365A (en) | 2005-06-02 | 2011-02-25 | Schering Corp | Combination of HCV protease inhibitors with a surfactant |
| US20070021351A1 (en) | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| WO2006130554A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| WO2006130552A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US20060276405A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis C |
| US20060287248A1 (en) | 2005-06-02 | 2006-12-21 | Schering Corporation | Asymmetric dosing methods |
| US20060281689A1 (en) | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| TW200738742A (en) | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
| EP1910378B1 (en) | 2005-07-20 | 2012-06-20 | Boehringer Ingelheim International GmbH | Hepatitis c inhibitor peptide analogs |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| AU2006276246B2 (en) | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
| RU2436787C2 (ru) | 2005-07-29 | 2011-12-20 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
| PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| US8012939B2 (en) | 2005-07-29 | 2011-09-06 | Tibotec Pharmaceuticals Ltd. Co | Macrocyclic inhibitors of hepatitis C virus |
| RU2419619C2 (ru) | 2005-07-29 | 2011-05-27 | Медивир Аб | Макроциклические ингибиторы вируса гепатита с |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| CN101273042B (zh) | 2005-07-29 | 2013-11-06 | 泰博特克药品有限公司 | 丙型肝炎病毒的大环抑制剂 |
| JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
| BRPI0614620A2 (pt) | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | compostos inibidores macrocìclicos do vìrus da hepatite c, uso dos mesmos, processo para preparar os referidos compostos, combinação e composição farmacêutica |
| TW200745061A (en) | 2005-07-29 | 2007-12-16 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis C virus |
| TWI375670B (en) | 2005-07-29 | 2012-11-01 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
| NZ565269A (en) | 2005-08-01 | 2010-03-26 | Merck & Co Inc | Macrocyclic peptides as HCV NS3 protease inhibitors |
| EP1915382A2 (en) | 2005-08-01 | 2008-04-30 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| ES2356776T3 (es) | 2005-10-11 | 2011-04-13 | Intermune, Inc. | Compuestos y métodos para inhibir la replicación del virus de la hepatitis. |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2007082131A1 (en) | 2006-01-09 | 2007-07-19 | Bristol-Myers Squibb Company | Process for the preparation of hydroxy substituted heterocycles |
| JP2009528353A (ja) | 2006-03-03 | 2009-08-06 | シェーリング コーポレイション | Ｈｃｖのプロテアーゼ阻害剤およびｉｒｅｓ阻害剤の医薬的組み合わせ |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US7582605B2 (en) | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
-
2007
- 2007-11-05 US US11/934,840 patent/US7772180B2/en active Active
- 2007-11-08 NZ NZ576817A patent/NZ576817A/en not_active IP Right Cessation
- 2007-11-08 CA CA002669310A patent/CA2669310A1/en not_active Abandoned
- 2007-11-08 WO PCT/US2007/084012 patent/WO2008060927A2/en not_active Ceased
- 2007-11-08 BR BRPI0718625-8A patent/BRPI0718625A2/pt not_active IP Right Cessation
- 2007-11-08 CN CN2007800416231A patent/CN101541784B/zh not_active Expired - Fee Related
- 2007-11-08 AU AU2007319435A patent/AU2007319435A1/en not_active Abandoned
- 2007-11-08 JP JP2009536467A patent/JP2010509359A/ja active Pending
- 2007-11-08 KR KR1020097011785A patent/KR20090082467A/ko not_active Withdrawn
- 2007-11-08 EA EA200900676A patent/EA200900676A1/ru unknown
- 2007-11-08 EP EP07864081.0A patent/EP2086963B1/en active Active
- 2007-11-08 MX MX2009004888A patent/MX2009004888A/es active IP Right Grant
- 2007-11-09 CL CL200703250A patent/CL2007003250A1/es unknown
- 2007-11-09 AR ARP070105019A patent/AR063653A1/es not_active Application Discontinuation
- 2007-11-09 TW TW096142550A patent/TW200826938A/zh unknown
- 2007-11-09 PE PE2007001545A patent/PE20081344A1/es not_active Application Discontinuation
-
2009
- 2009-04-21 IL IL198248A patent/IL198248A0/en unknown
- 2009-04-22 NO NO20091591A patent/NO20091591L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101541784B (zh) | 2013-04-24 |
| TW200826938A (en) | 2008-07-01 |
| IL198248A0 (en) | 2009-12-24 |
| EP2086963B1 (en) | 2015-09-16 |
| JP2010509359A (ja) | 2010-03-25 |
| PE20081344A1 (es) | 2008-09-18 |
| EA200900676A1 (ru) | 2010-02-26 |
| US20080119461A1 (en) | 2008-05-22 |
| MX2009004888A (es) | 2009-05-19 |
| WO2008060927A2 (en) | 2008-05-22 |
| US7772180B2 (en) | 2010-08-10 |
| CA2669310A1 (en) | 2008-05-22 |
| NZ576817A (en) | 2011-08-26 |
| BRPI0718625A2 (pt) | 2014-04-01 |
| CL2007003250A1 (es) | 2008-05-23 |
| NO20091591L (no) | 2009-07-28 |
| EP2086963A2 (en) | 2009-08-12 |
| WO2008060927A3 (en) | 2008-07-03 |
| AR063653A1 (es) | 2009-02-04 |
| CN101541784A (zh) | 2009-09-23 |
| AU2007319435A1 (en) | 2008-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20090082467A (ko) | Ｃ형 간염 바이러스 억제제 | |
| US7323447B2 (en) | Hepatitis C virus inhibitors | |
| KR101610418B1 (ko) | Ｃ형 간염 바이러스 억제제 | |
| KR101005958B1 (ko) | 간염 ｃ 바이러스 억제제 | |
| KR20090083462A (ko) | Ｃ형 간염 바이러스 억제제 | |
| EP2280958A1 (en) | Hepatitis c virus inhibitors | |
| CN102099359A (zh) | 丙型肝炎病毒抑制剂 | |
| EP1904516A2 (en) | Hepatitis c virus inhibitors | |
| JP2010508362A (ja) | Ｃ型肝炎ウイルスの阻害剤 | |
| JP2010508361A (ja) | Ｃ型肝炎ウイルスの阻害剤 | |
| JP2010508360A (ja) | Ｃ型肝炎ウイルスの阻害剤 | |
| AU2009236467B2 (en) | Hepatitis C virus inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20090608 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |